Valneva SE (NASDAQ:VALN - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $7.00, but opened at $7.48. Valneva shares last traded at $7.54, with a volume of 18,726 shares.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Valneva in a report on Friday, January 31st.
Get Our Latest Stock Report on VALN
Valneva Trading Down 14.4 %
The stock has a market cap of $542.01 million, a P/E ratio of -51.31 and a beta of 1.98. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock's fifty day moving average is $4.92 and its 200 day moving average is $5.64.
Institutional Investors Weigh In On Valneva
Several institutional investors have recently modified their holdings of VALN. ABC Arbitrage SA purchased a new stake in Valneva during the 4th quarter valued at $84,000. AlphaCentric Advisors LLC increased its position in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock valued at $717,000 after acquiring an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after acquiring an additional 30,859 shares during the period. 11.39% of the stock is owned by institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
